Pharmafile Logo
Pharmafocus logo
Advanced Search

UCB

Showing 15 posts of 80 posts found.

Aesica aims to double capacity and turnover with UCB plants

December 20, 2010
Manufacturing and Production Aesica, UCB, pharma manufacturing

UK contract manufacturer and ingredient supplier Aesica Pharmaceuticals is planning to double its production capacity with the acquisition of three …

News
systemic lupus erythematosus

UCB lupus candidate shows disease benefits

November 11, 2010
Benlysta, Lupus, UCB, epratuzumab, monoclonal antibody, systemic lupus erythematosus

A new monoclonal antibody targeting the autoimmune disease lupus is continuing to show a positive effect on sufferers, its manufacturer …

News

‘Therapeutic clusters’ collaboration launched

November 2, 2010
Research and Development ABPI, BIA, Immunology Initiative, Medical Research Council, Office for Strategic Co-ordination of Health and Research, Therapeutic Capability Clusters’, UCB, therapeutic clusters

Two initiatives linking the pharma industry and government-funded research and academia are to go ahead, with the aim of reviving …

News

UCB signs Parkinson’s research deal

October 12, 2010
Research and Development Parkinson's, Synosia Therapeutics, UCB, neurology

UCB has partnered with Synosia Therapeutics to develop two of the Swiss firm’s compounds for Parkinson’s disease.  Basel-based Synosia has …

News

Representing medium-sized pharma

September 16, 2010
Sales and Marketing European Medicines Group, UCB

UCB’s Matthew Speers is the new chairman of the European Medicines Group, which represents European-owned pharma companies in the UK. …

Feature

New products help lift UCB

August 3, 2010
Sales and Marketing 2010 financials, Q2, UCB

UCB’s newer products showed impressive growth in the first six months of this year, helping keep the Belgium-based biopharma firm’s …

News
Matthew_Speers

UCB’s Speers to lead European Medicines Group

July 19, 2010
Sales and Marketing European Medicines Group, UCB, appointment, sales and marketing

UCB Pharma’s managing director Matthew Speers has been elected chair of the European Medicines Group, taking over from Nigel Brooksby …

Appointment

UCB’s new lupus treatment promising

June 17, 2010
Research and Development Benlysta, Lupus, UCB, epratuzumab

A new monoclonal antibody treatment for lupus has shown promise in phase II trials, according to UCB. The biopharmaceutical company …

News

UCB’s Kola joins Astex board

June 5, 2010
Research and Development Astex, UCB, appointment, research and development

Dr Ismail Kola has joined the board of directors at UK biotech company Astex Therapeutics. Astex’s non-executive chairman Peter Fellner …

Appointment

Slow recovery expected for epilepsy market

May 27, 2010
Sales and Marketing Datamonitor, Keppra, UCB, epilepsy

The global market for epilepsy treatments is expected to make a slow recovery after a wave of patent expiries from …

News

UCB’s Roch Doliveux joins Innovative Medicines Initiative board

May 19, 2010
Research and Development UCB, appointment, research and development

UCB’s chief executive Roch Doliveux has joined the governing board of the Innovative Medicines Initiative. The IMI is a public-private …

Appointment
UCB

Generic Keppra hits UCB sales

March 3, 2010
Sales and Marketing 2009 financials, Keppra, UCB

UCB’s sales fell 13% in 2009 as the pharma company faced the first full year of generic competition in the …

News
Blog footer

Digital Pharma: UCB’s online epilepsy community

February 8, 2010
Medical Communications, Research and Development PatientsLikeMe, UCB, community, digital pharma, digital pharma research, patient information

UCB has launched an online community for US epilepsy patients to record ‘real-world’ experiences of the condition. In addition to …

Feature

Patient access scheme secures NICE approval for Cimzia

January 22, 2010
Sales and Marketing Cimzia, NICE, UCB, rheumatoid arthritis

UCB Pharma’s Cimzia has been recommended by NICE to treat rheumatoid arthritis – but only if a patient access scheme …

News

UCB and Novartis expand alliance in Germany

September 1, 2009
Sales and Marketing Germany, Novartis, UCB

UCB and Novartis have extended their partnership in Germany with a new licensing deal for the cardiovascular and diabetes drug …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025